AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.
The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term cognitive and memory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback